Introduction:
The journey to parenthood through IVF is as emotional as it is clinical—demanding precision, patience, and unwavering support. Behind every successful IVF story are organizations working tirelessly to advance fertility care through innovation, research, technology, and compassion. On the occasion of World IVF Day 2025, we celebrate these changemakers with “Lifelines of IVF: Organizations Supporting Every Step”—a curated showcase of companies that are making a meaningful difference across the IVF spectrum. From diagnostics and drug development to lab technology and patient support, these organizations are helping couples turn hope into reality.
Bharat Serums and Vaccines (A Mankind Group Company) is a leading biopharmaceutical firm offering world-class, research-driven fertility treatments to couples seeking assisted reproductive therapy (ART). Their recombinant hormone therapies provide consistent dosage and purity, leading to a more predictable ovarian response.
With IVF cycles in India rising from 1.5 lakh in 2015 to 3.3 lakh in 2024, advancements like personalized IVF protocols, the Freeze-All strategy, and embryo vitrification have played a key role in improving outcomes. Technologies such as time-lapse embryo imaging, genetic testing, non-invasive monitoring, gene editing, wearable hormone monitors, and AI in embryology are making ART more effective and accessible.
Through scientific progress and patient-centric care, Bharat Serums and Vaccines is helping more couples explore the joy of parenthood with confidence and hope.
By: Mr. Sanjiv Navangul, MD & CEO, BSV (A Mankind Group Company)
Intas Pharmaceuticals is a key contributor to reproductive healthcare in India, offering high-quality, evidence-based medications specifically designed for infertility management. As one of the country’s top 10 pharmaceutical companies with a 2.9% market share, Intas has established a strong presence in the fertility space.
Its portfolio includes hormone-based injectables such as Intas HCG 5000 IU (used to trigger ovulation and support sperm production), Intas FSH 150 IU (for follicle development during IVF), and Intas HMG 150 IU (to aid egg maturation and improve sperm count). These formulations are routinely used across IVF, IUI, and ART procedures to support various stages—oocyte retrieval, ovulation, and embryo transfer.
In addition to product innovation, Intas actively partners with fertility clinics and specialists through education, training, and awareness initiatives. Their mission is to make reliable, affordable fertility treatments more accessible—empowering thousands of couples on their path to parenthood.
Samarth Life Sciences is committed to transforming fertility healthcare through innovation, data-driven solutions, and an empathetic approach that enhances both doctor and patient experiences. With a mission to support every step of the IVF journey, the company designs products that empower specialists to overcome clinical challenges and help patients realize their dreams of parenthood.
Its fertility-focused portfolio includes Gonadotropins and GnRH antagonists—critical tools in assisted reproductive protocols. Beyond innovation, Samarth is equally dedicated to improving access and affordability across India, ensuring that fertility treatments are not limited by geography or cost.
By combining scientific rigor with social responsibility, Samarth Life Sciences aims to eliminate the stigma surrounding infertility and make quality fertility care a reality for all.
By: Mr. Mahabaleshwar Kotabagi, Head - Fertility Cluster, Samarth Life Sciences
With over five decades of scientific excellence, Gufic Biosciences is committed to becoming a global leader in high-quality, affordable reproductive health solutions. Its Ferticare division focuses on developing clinically validated IVF treatments, manufactured at EU cGMP-approved facilities in India, including its advanced Indore plant.
In the fertility space, Gufic has introduced breakthrough injectables such as Supergraf, an ultra-purified HMG formulation for ovarian stimulation, and Puregraf, a trusted gonadotropin brand widely used by fertility specialists. Notably, Guficin Alpha, designed for recurrent implantation failure, stands out as a first-of-its-kind therapy that significantly improves implantation success.
Driven by real-world data, clinical validation, and global market expansion, Gufic supports IVF journeys by offering evidence-based therapies that enhance outcomes, improve access, and lower treatment costs for both clinicians and couples.
By: Dr Rajeev Agarwal, President Fertility Cluster, Gufic Biosciences ltd Under writeup of Gufic
Shree Venkatesh International Ltd. is a trusted name in India’s pharmaceutical industry, leading the way in IVF and reproductive healthcare. With a mission to empower women and support families globally, the company offers a wide range of high-quality hormonal formulations—including HCG, HMG, FSH, Cetrorelix, Triptorelin, and Progesterone injections—produced in its WHO-GMP-certified facility.
These advanced formulations are integral to fertility treatments worldwide. Through a strong international distribution network, Shree Venkatesh contributes to reproductive care protocols and delivers reliable, world-class solutions to clinicians and patients alike.
More than a pharmaceutical provider, Shree Venkatesh becomes a part of the emotional and hopeful journey of building families—committed not only to quality but to the dreams of every couple it serves.
LifeCell Diagnostics is redefining fertility care through advanced diagnostics that bring clarity to one of life’s most meaningful journeys—starting a family. With a strong legacy in healthcare innovation, LifeCell now empowers doctors and couples with accurate, timely insights that enhance treatment outcomes.
Its key offerings include Preimplantation Genetic Testing (PGT) to identify healthy embryos, ERscope to determine the optimal implantation window, and specialized diagnostics like DICE for chronic endometritis, DNA fragmentation analysis, and Y chromosome microdeletion testing.
LifeCell stands apart in its mission to improve IVF success rates, reduce failed cycles, and make cutting-edge diagnostics more affordable and accessible. By collaborating with top clinics across India and abroad, it delivers non-invasive and personalized solutions tailored to each patient's needs.
Looking ahead, LifeCell is embracing AI-powered tools and early fertility screening—shaping a future where every IVF journey starts with clarity and ends in hope.
Founded in 2011 by first-generation entrepreneurs Rakesh Sharma, Subhamoy Dastidar, and Gulshan Bakhtiani, Lilac Insights is a leading genetic diagnostics company dedicated to advancing fertility care through evidence-based genetic testing solutions. With expertise in genetic diagnostics, the organization supports IVF clinicians and couples with accurate, accessible, and scalable technologies.
As infertility rises due to lifestyle changes, delayed parenthood, and increasing awareness, genetic testing has become a key part of IVF journeys. Lilac has screened over 30,000 embryos using advanced Pre-implantation Genetic Testing methods like ni-PGT-A, PGT-A, PGT-M, and PGT-SR. Its comprehensive portfolio also includes Carrier Screening, machine learning-based Endometrial Receptivity Testing (ERT), and targeted gene panels.
Backed by a team of expert scientists, geneticists, and counselors, and trusted by over 500 IVF centers, Lilac Insights continues to bring global standards to fertility care—helping couples and clinicians make timely, informed decisions on the path to parenthood.
CooperSurgical Fertility Solutions, the fertility division of CooperSurgical, is a global leader in assisted reproductive technology (ART), offering a complete portfolio of cutting-edge products, technologies, and genetic services across the IVF spectrum.
With a legacy built on trusted brands like ORIGIO, SAGE, Humagen, K-Systems, RI, Wallace®, LifeGlobal®, and CooperGenomics, the company delivers a seamless ecosystem of consumables, lab equipment, and embryo testing—designed to support fertility clinics at every step of the ART journey. From tailored culture media and sperm selection tools like ZyMōt, PICSI, and Sperm Slow to advanced lab management software like RI Witness, their solutions are geared to enhance clinical outcomes and lab efficiency.
Through seven global Centers of Excellence—including one in Mumbai—CooperSurgical offers hands-on training, next-gen workshops, and evidence-based learning to bridge the global skill gap in fertility care. With a deep focus on innovation, education, and collaboration, CooperSurgical Fertility Solutions continues to empower clinics and shape the future of fertility care for generations to come.
Shinelife Meditec is a proudly Make in India medical device manufacturer, dedicated to advancing fertility care through innovative, precise, and affordable solutions. The company’s mission is to empower IVF and infertility labs with globally benchmarked equipment, tailored to meet the unique needs of India and other emerging economies.
Shinelife designs and manufactures a complete range of ART (IVF) lab devices through robust in-house R&D, regulatory, and design teams focused on accuracy, usability, and long-term serviceability. With a scalable and quality-driven manufacturing model, the company aspires to lead globally in affordable ART lab technology.
Recognized with the Best Make in India Fertility Product Line award at the IVF Excellence Awards 2025 by Voice of Healthcare, Shinelife Meditec continues its commitment to enabling high-success fertility care—driven by innovation, accessibility, and patient-centered values.
Celagenex is transforming reproductive care by leveraging the power of endogenous metabolites to address chronic and complex lifestyle diseases. With a unique approach that targets the root causes through epigenetic signaling and molecular stability, the organization is bringing a fresh perspective to fertility science.
Focused on unmet needs in reproductive health, Celagenex has developed patented and proprietary molecules backed by global research and clinical insights. Their key innovations include EQOQ—advancing the science of ageing oocytes and embryo quality; BYZEPTA—a non-hormonal approach to PCOS management; and Oligonorm—targeting sperm health and central spermatogenesis.
With 48 global patents applied for and 22 already granted across the US and India, Celagenex continues to push the boundaries of fertility solutions. By partnering with clinicians and embracing science-driven progress, the organization is committed to improving outcomes and offering hope to couples on their IVF journey.
Revvity is transforming fertility, prenatal, and newborn care through cutting-edge diagnostic innovations that enable early, personalized medical decisions. With a strong foundation in maternal-fetal health and newborn screening, the company delivers a complete suite of solutions—from sample collection cards and reagents to diagnostic instruments, software, and managed lab services.
In the IVF space, Revvity supports clinicians with advanced instruments and reagents that assist in assessing embryo viability and performing genetic screening, enabling informed choices during assisted reproduction. Its high-throughput platforms further empower early risk detection for chromosomal abnormalities, pre-eclampsia, and structural anomalies during prenatal screening.
By enabling the identification of hundreds of rare yet treatable childhood-onset conditions from day one, Revvity is committed to giving every child a healthier start—delivering hope through early insight, innovation, and long-term impact.
Disclaimer:
“Lifelines of IVF: Organizations Supporting Every Step” is a curated editorial feature intended purely for informational and awareness purposes. It does not represent an endorsement, ranking, or certification by Voice of Healthcare. We recognize that numerous other organizations are also making valuable contributions in the IVF and fertility care space. The inclusion or order of appearance of organizations in this listicle does not imply preference or priority. Readers are encouraged to conduct their own research for comprehensive perspectives.